scholarly journals STUDY OF IMMUNE RESPONSE AFTER HEPATITIS B VACCINATION IN DOCTORS

2020 ◽  
Vol 4 (6) ◽  
Author(s):  
B.L. Meena ◽  
Nikhil Gandhi ◽  
M.P. Sharma
Keyword(s):  
Immune Response ◽  
Hepatitis B ◽  
Booster Dose ◽  
Booster Vaccination ◽  
Primary Vaccination ◽  
Vaccination Status ◽  
Hepatitis B Vaccine ◽  
Hepatitis B Vaccination ◽  
Age Group ◽  
Seroprotection Rate

Background: Aim of our study was to evaluate the immune response after hepatitis B vaccination and to determine the duration of protective levels of HBsAb titre in doctors. From our study we concluded that hepatitis-B vaccine gives protection for more than 10 years after primary vaccination and booster dose of Hepatitis-B vaccine is not required in immunocompetent persons after primary vaccination. Method: In this study total 100 doctors of our institution were included who were vaccinated against hepatitis B. Data were obtained regarding age, sex, weight, height, BMI and duration of vaccination period. Doctors with no prior vaccination or incomplete vaccination or those who took booster vaccination were excluded from this study. Results: The mean titre was observed to be higher in 30 to 34 years of age group (584.42±4.03.21) as compared to age group of less than 25 and greater than 40 years. Moreover, males were observed to have higher mean titre as compared to females. (411.64± 417.27 vs 333.66± 431.49) but not statistically significant.  Similar with age and sex, duration of vaccination status was also not statistically significant. When we compared the  duration of vaccination status with  age group , mean titre was more in ≥30 years of age group as compared to <30 years (younger age groups) but statistically significant relation was observed only with the 1 month to <5 years of duration. Conclusion: From our study we concluded that hepatitis-B vaccinegives protection for more than 10 years after primary vaccination and booster dose of Hepatitis-B vaccine is not required inimmuno-competent persons after primary vaccination. Keywords: HbsAg titre , HepatitsB vaccine , seroprotection rate.

scholarly journals Antibody responses after hepatitis B vaccination among maintenance haemodialysis patients

1970 ◽  
Vol 37 (3) ◽  
pp. 88-91 ◽  
Author(s):  
K Nahar ◽  
M Jahan ◽  
A Nessa ◽  
S Tabassum
Keyword(s):  
Hepatitis B ◽  
Antibody Titer ◽  
Primary Vaccination ◽  
Carrier State ◽  
Hepatitis B Vaccine ◽  
Hepatitis B Vaccination ◽  
Seroprotection Rate ◽  
Hbv Vaccine ◽  
Maintenance Haemodialysis ◽  
B Virus

In haemodialysis patients, hepatitis B virus infection has higher mortality and is more likely to result in the carrier state. Although Hepatitis B vaccine is effective in producing protection against HBV infection, the antibody response may be variable. In this study, seroprotection rate of hepatitis B vaccine in maintenance haemodialysis patients was studied after primary vaccination and after completion of the full vaccine regime. 50 unvaccinated patients on maintenance haemodialysis were included in this study. Patients negative for HBsAg, Anti-HBc (total) and Anti-HCV were vaccinated with 40μg of Engerix B following a schedule of 0, 1, and 2 months. The antibody titer was tested at 3rd month and if the titer was <10 or between 10-100 mIU/ml, they were given another 4th dose of vaccine at 6th month, and their antibody titer was tested again at 7th month. In maintenance haemodialysis patients, the response rate to HBV vaccine was 44% after the primary vaccination and 80% after completion of the full vaccine regime. DOI: http://dx.doi.org/10.3329/bmrcb.v37i3.9119 BMRCB 2011; 37(3): 88-91

scholarly journals Immune Response Among the Children to Hepatitis B Vaccination: A Community-based Study in Bangladesh

2018 ◽  
Vol 44 (2) ◽  
pp. 103-108
Author(s):  
Mohammad Monir Hossain ◽  
Ahmed Nawsher Alam ◽  
Mahmuda Siddiqua ◽  
Ayesha Siddika ◽  
Afzalun Nessa
Keyword(s):  
Immune Response ◽  
Hepatitis B ◽  
Booster Dose ◽  
Protective Efficacy ◽  
Hepatitis B Vaccination ◽  
Age Group ◽  
Breakthrough Infection ◽  
Protective Level ◽  
Hbv Vaccine ◽  
Public Health Burden

Hepatitis B virus infection is a vaccine preventable infection of liver which remains a key public health burden globally. The development of Anti-HBs titre greater than or equal to 10 IU/L is considered as protective immunity and any titre less than 10 IU/L as non-protective following HBV vaccination. There is no comprehensive and authentic data regarding the immune response even 10 years after the integration of the HBV vaccine in to the EPI programme in Bangladesh and specifically, in Brahmonbaria district. The study was also aimed to assess the long term immune response among HBV vaccinated children. Blood sample from 500 vaccinated children were tested for Anti-HBs, and anti-HBc. Sero negative children were given 1 dose of HBV vaccine as a booster. Samples from booster vaccine were taken one month later and tested for anti Hbs titre. Anti HBs titre was found below protective level in about 46.0% (230/500) participants. Sero-protection rate decreased to 72.2% in 5 to 6 years age group which further decreased to 58.3% in 7 to 9 years age group and increased again to 69.5% in 10 to 12 years age group children. On the other hand, the mean anti Hbs titre was 97.72 IU/L initially and then increased with the increasing of age from 165.40 IU/L to 196.67 IU/L. Breakthrough infection of HBV was seen in 1.2% (6/500) participants measuring by anti HBc which indicated protective efficacy of HBV vaccine was about 98.8% (494/500). Sero negative participants were given a booster dose; 93.6% (131/140) participants showed boosting of mean anti HBs titre upto 804.92 IU/L which was below protective level (<10 IU/L) before booster dose. Anti-HBs titre goes below with the increase of age after vaccination. Most of the participants had immunological memory which will boost antibody titre after any exposure, so routine booster dose is not needed. But non-responder to vaccination should screen after primary vaccination because of chance of breakthrough infection.

scholarly journals Hepatitis B vaccination status and vaccine immune response among children in rural Senegal

2019 ◽  
Vol 29 (Supplement_4) ◽  
Author(s):  
L Perieres ◽  
M Coste ◽  
S Ndiour ◽  
P Halfon ◽  
C Sokhna ◽  
...  
Keyword(s):  
Immune Response ◽  
Hepatitis B ◽  
Chronic Infection ◽  
Vaccination Status ◽  
Hbv Infection ◽  
Hepatitis B Vaccination ◽  
Chronic Hbv Infection ◽  
Hbv Vaccination ◽  
Chronic Hbv ◽  
Vaccine Immunity

Abstract Background Hepatitis B vaccination during childhood is key to reduce the prevalence of Hepatitis B virus (HBV) infection. In Senegal, a highly endemic country, the three-dose hepatitis B vaccine and the birth dose vaccine were introduced in the Expanded Programme on Immunization (EPI) in 2004 and 2016 respectively. This study aimed to determine chronic HBV infection prevalence, hepatitis B vaccination status and vaccine immunity among children in Senegal. Methods A cross-sectional study including HBV screening was conducted at home among children aged 6 months to 15 years (i.e. born after the introduction of the HBV vaccine in the EPI) in the rural zone of Niakhar. Dried Blood Spot (DBS) samples were collected for the detection of HBsAg, anti-HBc Ab and anti-HBs Ab using chemoluminescence. Vaccination status was assessed using information on vaccination cards. Detectable vaccine immunity was defined with an adjusted DBS threshold of DOI≥0.36 IU/mL (corresponding to 10 IU/mL in venous blood sampling). Results Between October and December 2018, 455 children were enrolled. Preliminary results show that 7/455 (1.5%) had been in contact with HBV (positive anti-HBc Ab) and 5/455 (1.1%) had chronic HBV infection (positive HBsAg). Only 161/455 (35.4%) children had a vaccination card available. Among those, 150/161 (93.2%) received at least 3 doses of hepatitis B vaccine, of which 83/150 (55.3%) had detectable vaccine immunity. The proportion of children with detectable vaccine immunity was significantly higher in children &lt;5 years than in children aged 5-9 and 10-15 (72.3% versus 47.3%, p = 0.006 and 72.3% versus 14.3%, p &lt; 0.001). Conclusions Preliminary results suggest a low prevalence of HBV chronic infection among children born after the introduction of HBV vaccination in Senegal. However, detectable vaccine immunity rapidly decreases with age among vaccinated children, signalling a need for further studies on the immune response to HBV vaccination in this context. Key messages HBV chronic infection is low among children born after the introduction of HBV vaccination in Senegal. Further studies on the immune response to HBV vaccination in this context are needed.

scholarly journals Effects of hepatitis B vaccine boosters in different levels of epidemic areas on anti-HBs-negative children after primary vaccination

2020 ◽  
Author(s):  
Lu Zhu ◽  
Kangli Ye ◽  
Yuanyuan Zheng ◽  
Yan Qiu ◽  
Zikang Wu ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Booster Vaccination ◽  
Primary Vaccination ◽  
Hepatitis B Vaccine ◽  
Booster Immunization ◽  
Group Iii ◽  
Group I ◽  
Epidemic Area ◽  
High Prevalence ◽  
Different Levels

Introduction. The widespread of hepatitis B virus is a severe global public problem, and the infant hepatitis B vaccine has been proved effective. But the failure of the immune response was reported in studies, and boosters were recommended. There were few studies about the effect of hepatitis B vaccine boosters in different levels of the epidemic area. Hypothesis. Booster immunization is recommended because there may be a lack of immunization in infants vaccinated with the hepatitis B vaccine. In order to verify the effectiveness of booster immunization, this study hypothesized that it worked well in different levels of endemic areas. Aim. To evaluate the effects of hepatitis B vaccine boosters on children from the areas with different prevalence of hepatitis B whose hepatitis B surface antibody (anti-HBs) were negative (<10 mIU ml−1). Methodology. A total of 940 children were initially enrolled in screening; however, 421 were excluded. The participants were divided into three groups according to the different areas they come from: group I, low epidemic area; group II, middle epidemic area; and group III, high epidemic area. In total, 519 subjects were administered three doses of booster hepatitis B vaccine (0–1–6 months, 10 µg). The antibody titre changes were examined at four time points: 1 month after dose 1, 1 month, 1 year and 5 years after dose 3. Results. The protective seroconversion rates in three groups were 96.30, 97.16, 96.63% at 1 month after dose 1, and 100.00, 100.00, 100.00% at 1 month after dose 3, and 97.79, 100.00, 98.50% at 1 year after dose 3, and 90.77, 93.67, 93.59% at 5 years after dose 3 (P>0.05). Conclusions. This study demonstrates that three doses of booster vaccination have a longtime effect, no matter whether it is in low, middle or high prevalence areas in which subjects live.

scholarly journals Review of Hepatitis B Vaccination in Children of Workers of an Oil & Gas Industry in Lho'seumawe and Lho'sukon, North Aceh

2018 ◽  
Vol 34 (7-8) ◽  
pp. 209-15
Author(s):  
Chairul Adillah Harahap ◽  
Sari Leyli Harahap ◽  
Chairuddin P. Lubis ◽  
Ahmad Judin
Keyword(s):  
Immune Response ◽  
Hepatitis B ◽  
Medical Records ◽  
Hepatitis B Vaccination ◽  
Age Group ◽  
Gas Industry ◽  
The Third ◽  
Hepatitis B Vaccines ◽  
Fourth Dose ◽  
Oil Gas

We describe a retrospective study on hepatitis-B immunization in the Indonesian workers' children of Mobil-Oil Indonesia Lho' Seumawe and Lho'sukon, North Aceh. Data were obtained from medical records and included all children in the 0-15 years age group who had been immunized against hepatitis B types and schedules of vaccines, pre-immunization seromarkers, and anti HBsAb after the third immunization were recorded. For hundred and twenty children had received three doses of,hepatitis B vaccines; 180 children had them at 0, 1 and 2 months and the rest at 0, 1 and 6 months. Type of vaccine used was hunian plasma derived vaccine with a dosage of 5 µg per shot All of them (except the newborns) were tested and had seromarkers negative to hepatitis 8 infection prior to immunization. Testing for immune response (HBsAb) 2-6 months after the third immunization could only be done in 213 children, where 168 (78.9%) showed HBsAb titer> 10 miU/ml, 5 (2,30Al) had HBsAb < 10 miU/ml, and the remaining 40 (18,8%) showed no seroconversion. Of those 40 children who did not seroconversed, 31 were given a fourth dose, and 14 children were retested for their HBsAb titre. Seven children had positive responses and the rest remained negative.

Hepatitis B vaccine and the need for a booster dose after primary vaccination

Vaccine ◽  
2017 ◽  
Vol 35 (46) ◽  
pp. 6302-6307 ◽  
Author(s):  
Claudia Pileggi ◽  
Rosa Papadopoli ◽  
Aida Bianco ◽  
Maria Pavia
Keyword(s):  
Hepatitis B ◽  
Booster Dose ◽  
Primary Vaccination ◽  
Hepatitis B Vaccine

Requirement of a Booster Dose of Hepatitis B Vaccine in Children With Thalassemia After 5 Years of Primary Vaccination: A Prospective Study

2021 ◽  
Vol 58 (3) ◽  
pp. 237-240
Author(s):  
Sunil Gomber ◽  
Ravinder Yadav ◽  
Pooja Dewan ◽  
V. G. Ramachandran ◽  
A. S. Puri
Keyword(s):  
Hepatitis B ◽  
Prospective Study ◽  
Booster Dose ◽  
Primary Vaccination ◽  
Hepatitis B Vaccine ◽  
A Prospective Study
Sign in / Sign up

Export Citation Format

Share Document